Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Kidney biopsy in lupus nephritis after achieving clinical renal remission: paving the way for renal outcome assessment.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Publication Information:
      Oxford University Press
    • Publication Date:
      2022
    • Collection:
      Dipòsit Digital de la Universitat de Barcelona
    • Abstract:
      The role of repeat kidney biopsy in lupus nephritis (LN) with renal remission is unclear. The aim of this study was to assess this role in a real-life scenario. This retrospective, single-centre study included 56 patients with LN diagnosed from 1998 to 2019, with an initial kidney biopsy (KB1) at the onset of LN and a second kidney biopsy (KB2) after achieving renal remission. A total of 51 (91.1%) patients were women with a median age of 29.9 years [interquartile range (IQR) 23.4-40.6] at the time of LN diagnosis. KB2s were performed after 41.1 months (IQR 30.1-52.5) of KB1. At the time of KB2, complete renal response was achieved in 51 (91.1%) patients. The median activity index decreased from a baseline value of 6.5 (IQR 2.8-11) to 0 (IQR 0-2) (P < .001). The chronicity index worsened from 1 (IQR 0-2) to 2 (IQR 1-3) (P = .01). In patients with proliferative/mixed forms at KB2, the chronicity index median value increased to 3 (IQR 1.5-4), as well as interstitial fibrosis and tubular atrophy [Formula: see text]25%, from 5.4% to 13.5%. Persistent histological active LN (activity index ≥2) was present in 11 (19.6%) KB2s. There were no differences when comparing immunological parameters between both groups (activity index ≥2 versus <2) at KB2, nor in the percentage of patients who presented renal flare. Immunosuppressive treatment was withdrawn in 35 (62.5%) patients and maintained/switched in 21 (37.5%). Afterward, new renal flare occurred in 9 patients per group (25.7% and 43%, respectively), after a median time of 39 months (IQR 6.5-55) and 7 months (IQR 6-30), respectively. There was no difference in the number of patients who developed chronic kidney disease [n = 14 (25%)] according to the treatment. In conclusion, KB2 provides valuable information to guide immunosuppressive maintenance therapy.
    • File Description:
      9 p.; application/pdf
    • Relation:
      Reproducció del document publicat a: https://doi.org/10.1093/ckj/sfac150; Clinical Kidney Journal, 2022, vol. 15, num. 11, p. 2081-2088; https://doi.org/10.1093/ckj/sfac150; https://doi.org/10.1093/ckj/sfad038; https://hdl.handle.net/2445/201623; 731019; 9329721
    • Online Access:
      https://hdl.handle.net/2445/201623
    • Rights:
      cc-by-nc (c) Lledó, Gema et al., 2022 ; https://creativecommons.org/licenses/by-nc/4.0/ ; info:eu-repo/semantics/openAccess
    • Accession Number:
      edsbas.6FC98E86